Johnson & Johnson
While J&J has dominated the talc powder market for more than 100 years the products contributed to a mere 0.5% of its revenue of $76.5bn last year.Photograph: Mike Blake/Reuters

Johnson & Johnson reported a 35.3% fall in second-quarter profit on Thursday as demand for its medical devices was hammered by hospitals putting off non-urgent procedures such as knee and hip replacement due to the COVID-19 pandemic.

Johnson & Johnson to begin human trials of its experimental Covid-19 vaccine

corona vaccine
corona vaccine

The company, which is set to begin human trials of its experimental coronavirus vaccine this month, reported net earnings of $3.63 billion, or $1.36 per share, down from $5.61 billion, or $2.08 per share, a year earlier.

However, the company raised its full-year adjusted profit forecast to $7.75 to $7.95 per share, from its prior estimate of $7.50 to $7.90 per share.